Advertisement

Tumor Biology

, Volume 37, Issue 2, pp 2257–2265 | Cite as

MicroRNA-related single-nucleotide polymorphism of XPO5 is strongly correlated with the prognosis and chemotherapy response in advanced non-small-cell lung cancer patients

  • Ji-Qun Geng
  • Xiao-Chen Wang
  • Long-Fei Li
  • Jun Zhao
  • Song Wu
  • Gui-Ping Yu
  • Kou-Jun Zhu
Original Article

Abstract

This study was performed to investigate if the microRNA-related single-nucleotide polymorphisms (miR-SNPs) of XPO5 gene predicted the prognosis and pathological features of advanced non-small-cell lung cancer patients receiving chemotherapy. A total of 131 advanced non-small-cell lung cancer (NSCLC) patients were recruited. MicroRNA (miRNA) binding site prediction software was adopted for the prediction and screening of SNPs in XPO5 and miRNA binding regions. Polymerase chain reaction (PCR) amplification was further performed. Time-dependent survival-free curves were constructed using the Kaplan–Meier technique. Univariate and the multivariate survival analyses were conducted for confirmation of prognostic factor for advanced NSCLC patients receiving chemotherapy. There were no significant differences of SNP distribution frequencies between groups, without statistical significance (P > 0.05). Included clinical pathological features and chemotherapy regimens showed no apparent statistical significance in influencing the curative effect of chemotherapy in advanced NSCLC patients (all P > 0.05). While the objective response rate (ORR) in patients who carried AA and AC genotype was 35.48 and 51.22 %, respectively, with statistically significant difference (P < 0.05). Univariate survival analysis indicated that patients who carried AA genotype showed a significantly lower 5-year survival rate to those who carried AC genotype (P < 0.05). And, considering pathological features, statistical significance was found in patients with different pathological types, lymph node metastasis, differentiation degree, T staging, and pathological staging (all P < 0.05). Multivariate analysis results indicated that the SNP sites of rs11077 might be an independent prognostic factor of advanced NSCLC patients receiving chemotherapy (risk ratio [RR] = 0.346; 95 % confidence interval [95 % CI] = 0.174–0.685, P = 0.002). Other clinical features were all considered to have no apparent effect in influencing the prognostic outcomes of advanced NSCLC patients receiving chemotherapy except lymph node metastasis (P < 0.05). miR-SNP rs11077 of XPO5 may be independently connected with the prognosis and chemotherapy response of advanced NSCLC patients, and patients with AC genotype have relatively improved prognostic outcomes and better curative effect of chemotherapy than those with AA allele of XPO5. Further, lymph node metastasis may be also involved in influencing the prognosis of advanced NSCLC patients.

Keywords

XPO5 Advanced non-small-cell lung cancer MicroRNA-related single-nucleotide polymorphism Prognosis 

Notes

Acknowledgments

We would like to thank the doctors and nurses from the Fourth People’s Hospital of Wuxi City, Jiangnan University, The Affiliated Jiangyin Hospital of Southwest University Medical College, The First Affiliated Hospital of Soochow University, and The Affiliated Xuzhou Hospital of Jiangsu University for helping in data and blood sample collection. We also thank the reviewers for their precious comments on this paper.

Conflicts of interest

None

References

  1. 1.
    Peters S, Adjei AA, Gridelli C, Reck M, Kerr K, Felip E, et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23 Suppl 7:vii56–64.CrossRefPubMedGoogle Scholar
  2. 2.
    Govindan R, Ding L, Griffith M, Subramanian J, Dees ND, Kanchi KL, et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell. 2012;150:1121–34.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Zhang WC, Shyh-Chang N, Yang H, Rai A, Umashankar S, Ma S, et al. Glycine decarboxylase activity drives non-small cell lung cancer tumor-initiating cells and tumorigenesis. Cell. 2012;148:259–72.CrossRefPubMedGoogle Scholar
  4. 4.
    Jiang YW, Chen LA. microRNAs as tumor inhibitors, oncogenes, biomarkers for drug efficacy and outcome predictors in lung cancer (review). Mol Med Rep. 2012;5:890–4.PubMedPubMedCentralGoogle Scholar
  5. 5.
    Fukumoto K, Taniguchi T, Usami N, Kawaguchi K, Fukui T, Ishiguro F, et al. The ABO blood group is an independent prognostic factor in patients with resected non-small cell lung cancer. J Epidemiol. 2015;25:110–6.CrossRefPubMedGoogle Scholar
  6. 6.
    Pu X, Roth JA, Hildebrandt MA, Ye Y, Wei H, Minna JD, et al. MicroRNA-related genetic variants associated with clinical outcomes in early-stage non-small cell lung cancer patients. Cancer Res. 2013;73:1867–75.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Hu Z, Chen J, Tian T, Zhou X, Gu H, Xu L, et al. Genetic variants of miRNA sequences and non-small cell lung cancer survival. J Clin Invest. 2008;118:2600–8.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Lin M, Gu J, Eng C, Ellis LM, Hildebrandt MA, Lin J, et al. Genetic polymorphisms in MicroRNA-related genes as predictors of clinical outcomes in colorectal adenocarcinoma patients. Clin Cancer Res. 2012;18:3982–91.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Trang P, Weidhaas JB, Slack FJ. MicroRNAs as potential cancer therapeutics. Oncogene. 2008;27 Suppl 2:S52–7.CrossRefPubMedGoogle Scholar
  10. 10.
    Vasudevan S, Tong Y, Steitz JA. Switching from repression to activation: microRNAs can up-regulate translation. Science. 2007;318:1931–4.CrossRefPubMedGoogle Scholar
  11. 11.
    Leaderer D, Hoffman AE, Zheng T, Fu A, Weidhaas J, Paranjape T, et al. Genetic and epigenetic association studies suggest a role of microRNA biogenesis gene exportin-5 (XPO5) in breast tumorigenesis. Int J Mol Epidemiol Genet. 2011;2:9–18.PubMedGoogle Scholar
  12. 12.
    Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 2006;6:259–69.CrossRefPubMedGoogle Scholar
  13. 13.
    Ding C, Li C, Wang H, Li B, Guo Z. A miR-SNP of the XPO5 gene is associated with advanced non-small-cell lung cancer. Onco Targets Ther. 2013;6:877–81.PubMedPubMedCentralGoogle Scholar
  14. 14.
    Lund E, Guttinger S, Calado A, Dahlberg JE, Kutay U. Nuclear export of microRNA precursors. Science. 2004;303:95–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435:834–8.CrossRefPubMedGoogle Scholar
  16. 16.
    Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A. 2004;101:2999–3004.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Wu X, Xiao H. miRNAs modulate the drug response of tumor cells. Sci China C Life Sci. 2009;52:797–801.CrossRefPubMedGoogle Scholar
  18. 18.
    Yi R, Doehle BP, Qin Y, Macara IG, Cullen BR. Overexpression of exportin 5 enhances RNA interference mediated by short hairpin RNAs and microRNAs. RNA. 2005;11:220–6.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Zeng Y, Cullen BR. Structural requirements for pre-microRNA binding and nuclear export by Exportin 5. Nucleic Acids Res. 2004;32:4776–85.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Thompson L. World Health Organization classification of tumours: pathology and genetics of head and neck tumours. Ear Nose Throat J. 2006;85:74.PubMedGoogle Scholar
  21. 21.
    Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2007;2:706–14.CrossRefPubMedGoogle Scholar
  22. 22.
    Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–16.CrossRefGoogle Scholar
  23. 23.
    Lund E, Dahlberg JE. Substrate selectivity of exportin 5 and Dicer in the biogenesis of microRNAs. Cold Spring Harb Symp Quant Biol. 2006;71:59–66.CrossRefPubMedGoogle Scholar
  24. 24.
    Farazi TA, Spitzer JI, Morozov P, Tuschl T. miRNAs in human cancer. J Pathol. 2011;223:102–15.CrossRefPubMedGoogle Scholar
  25. 25.
    Melo SA, Moutinho C, Ropero S, Calin GA, Rossi S, Spizzo R, et al. A genetic defect in exportin-5 traps precursor microRNAs in the nucleus of cancer cells. Cancer Cell. 2010;18:303–15.CrossRefPubMedGoogle Scholar
  26. 26.
    Campayo M, Navarro A, Vinolas N, Tejero R, Munoz C, Diaz T, et al. A dual role for KRT81: a miR-SNP associated with recurrence in non-small-cell lung cancer and a novel marker of squamous cell lung carcinoma. PLoS One. 2011;6:e22509.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12:735–42.CrossRefPubMedGoogle Scholar
  28. 28.
    Shimada Y, Saji H, Yoshida K, Kakihana M, Honda H, Nomura M, et al. Pathological vascular invasion and tumor differentiation predict cancer recurrence in stage IA non-small-cell lung cancer after complete surgical resection. J Thorac Oncol. 2012;7:1263–70.CrossRefPubMedGoogle Scholar
  29. 29.
    Nakayama J, Miyasaka K, Omatsu T, Onodera Y, Terae S, Matsuno Y, et al. Metastases in mediastinal and hilar lymph nodes in patients with non-small cell lung cancer: quantitative assessment with diffusion-weighted magnetic resonance imaging and apparent diffusion coefficient. J Comput Assist Tomogr. 2010;34:1–8.CrossRefPubMedGoogle Scholar
  30. 30.
    Li M, Wu N, Zheng R, Liang Y, Liu Y, Zhang W, et al. Primary tumor PET/CT [(1)(8)F]FDG uptake is an independent predictive factor for regional lymph node metastasis in patients with non-small cell lung cancer. Cancer Imaging. 2013;12:566–72.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Koike T, Koike T, Yamato Y, Yoshiya K, Toyabe S. Predictive risk factors for mediastinal lymph node metastasis in clinical stage IA non-small-cell lung cancer patients. J Thorac Oncol. 2012;7:1246–51.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Ji-Qun Geng
    • 1
  • Xiao-Chen Wang
    • 2
    • 3
  • Long-Fei Li
    • 4
  • Jun Zhao
    • 3
  • Song Wu
    • 2
  • Gui-Ping Yu
    • 2
  • Kou-Jun Zhu
    • 1
  1. 1.Department of Thoracic and Cardiac Surgery, The Fourth People’s Hospital of Wuxi CityJiangnan UniversityWuxiPeople’s Republic of China
  2. 2.Department of Thoracic and Cardiac SurgeryThe Affiliated Jiangyin Hospital of Southwest University Medical CollegeJiangyinPeople’s Republic of China
  3. 3.Department of Thoracic and Cardiac SurgeryThe First Affiliated Hospital of Soochow UniversitySuzhouPeople’s Republic of China
  4. 4.Department of Thoracic and Cardiac SurgeryThe Affiliated Xuzhou Hospital of Jiangsu UniversityXuzhouPeople’s Republic of China

Personalised recommendations